As litigation unfolds, this case will likely shape the future of GLP-1 access, telehealth innovation, and the balance between patient care and pharmaceutical market control.
Many post-op patients use medications to help with weight regain, appetite control, or metabolic issues
Unfortunately, evidence 31 shows that drastic and rapid weight losswhether from GLP-1 RA use, bariatric surgery, or diet-induced methodscan reduce LBM by up to 50% of the total weight lost
As for the price issue, Kongstvedt said that usually happens when a pharmaceutical protected by a patent has few competitors because we allow a free market in the U.S., unlike pretty much any other nation in the world. Combined with our third-party payment system in which most people are protected from the impact of that pricing when a drug is covered, it provides a powerful motivation to drug manufacturers to jack prices up until they actually can look down upon the International Space Station, Kongstvedt said.
Interestingly, certain classical inflammatory stimuliincluding lipopolysaccharide (LPS) and pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor- (TNF-) can, in turn, induce GLP-1 secretion